Morningstar
Merck Drug Gets Fast-Track Designation from FDA for Alzheimer's Treatment
Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...
WTKR
FDA approves drug for use in fighting Alzheimer's despite lingering questions from key panel
The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...
Seeking Alpha
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation
Axsome Therapeutics (AXSM) announced on Wednesday that the U.S. FDA has granted priority review for its marketing application seeking a label expansion for its depression therapy AXS-05 (Auvelity) in ...
STAT
New data confirm Novo drug did not slow Alzheimer’s progression
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Reuters
Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant
Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...
The New York Times
In New Dementia Trials, Ozempic’s ‘Miracle Drug’ Image Takes a Hit
The drug failed to slow the progression of early Alzheimer’s. Experts are trying to understand why. By Dana G. Smith and Dani Blum Over the past few years, scientists have learned that Ozempic and ...
Science Daily
A new drug could stop Alzheimer’s before memory loss begins
New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...